Real-world challenges in first-line treatment of metastatic EGFR-mutated non-small cell lung cancer

Barreto, Inês; Figueiredo, Sara; Tonin, Fernanda; Vilariça, Ana Sofia; Hasmucrai, Direndra; Alves, Paula

http://hdl.handle.net/10400.21/17243

Use this identifier to reference this record.

Name:	Description:	Size:	Format:
Real-world challenges in first-line treatment of metastatic EGFR-mutated non-small cell lung cancer.pdf		410.88 KB	Adobe PDF	Download

Send Feedback

Authors

Abstract(s)

Osimertinib, a third-generation tyrosine kinase inhibitor (TKI), was recently introduced in several countries, including Portugal (reimbursement in 2021), as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating proto-oncogene epidermal growth factor receptor mutations (EGFRm), after showing significant efficacy and safety when used in patients with EGFR-T790M resistance mutations. However, despite advances in personalized target treatments in this field, challenges regarding patients’ journey (e.g., therapy selection criteria, EGFR-TKI optimal sequencing, treatment beyond second-line) still exist.

Keywords

Lung cancer Non-small-cell lung cancer EGFR mutation Real-world data Tyrosine kinase inhibitors

URI

http://hdl.handle.net/10400.21/17243

Citation

Barreto I, Figueiredo S, Tonin FS, Vilariça AS, Hasmucrai D, Alves P. Real-world challenges in first-line treatment of metastatic EGFR-mutated non-small cell lung cancer. Port J Card Thorac Vasc Surg. 2023;30(3):9-11.